U.S. pharma giant copyright scrapped two experimental weight loss products last calendar year—a as soon as-each day tablet, lotiglipron, because of elevated liver enzymes as well as a two times-day by day pill, danuglipron, as a consequence of powerful Unintended effects—but CEO Albert Bourla has said the company is decided to “Engage in and